company background image
LBPH

Longboard PharmaceuticalsNasdaqGM:LBPH Stock Report

Market Cap

US$160.4m

7D

3.6%

1Y

n/a

Updated

19 Oct, 2021

Data

Company Financials +
LBPH fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LBPH Overview

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Longboard Pharmaceuticals
Historical stock prices
Current Share PriceUS$9.32
52 Week HighUS$7.39
52 Week LowUS$18.95
Beta0
1 Month Change0.32%
3 Month Change7.50%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-44.02%

Recent News & Updates

Jun 12
Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

May 10

Longboard Pharmaceuticals EPS beats by $0.29

Longboard Pharmaceuticals (LBPH): Q1 GAAP EPS of -$0.84 beats by $0.29.Cash and cash equivalents balance of $120.9M.Press Release

Shareholder Returns

LBPHUS PharmaceuticalsUS Market
7D3.6%2.1%4.0%
1Yn/a14.9%30.5%

Return vs Industry: Insufficient data to determine how LBPH performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LBPH performed against the US Market.

Price Volatility

Is LBPH's price volatile compared to industry and market?
LBPH volatility
LBPH Beta0
Industry Beta0.65
Market Beta1

Stable Share Price: LBPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: LBPH's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
202014Kevin Lindhttps://www.longboardpharma.com

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020.

Longboard Pharmaceuticals Fundamentals Summary

How do Longboard Pharmaceuticals's earnings and revenue compare to its market cap?
LBPH fundamental statistics
Market CapUS$160.45m
Earnings (TTM)-US$25.34m
Revenue (TTM)n/a

0x

P/S Ratio

-6.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LBPH income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$25.34m
Earnings-US$25.34m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.47
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did LBPH perform over the long term?

See historical performance and comparison

Valuation

Is Longboard Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

1.37x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LBPH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LBPH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LBPH is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: LBPH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LBPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LBPH is good value based on its PB Ratio (1.4x) compared to the US Pharmaceuticals industry average (3.1x).


Future Growth

How is Longboard Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-30.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LBPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LBPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LBPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LBPH is forecast to have no revenue next year.

High Growth Revenue: LBPH is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LBPH is forecast to be unprofitable in 3 years.


Past Performance

How has Longboard Pharmaceuticals performed over the past 5 years?

10.3%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: LBPH is currently unprofitable.

Growing Profit Margin: LBPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if LBPH's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare LBPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LBPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: LBPH has a negative Return on Equity (-21.57%), as it is currently unprofitable.


Financial Health

How is Longboard Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: LBPH's short term assets ($120.7M) exceed its short term liabilities ($3.3M).

Long Term Liabilities: LBPH has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: LBPH is debt free.

Reducing Debt: LBPH has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LBPH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: LBPH has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 241.2% each year.


Dividend

What is Longboard Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LBPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LBPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LBPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LBPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LBPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Kevin Lind (45 yo)

1.58yrs

Tenure

US$2,286,691

Compensation

Mr. Kevin R. Lind serves as President and Chief Executive Officer at Longboard Pharmaceuticals, Inc. since March 2020 and also serves as its director since January 2020. Mr. Lind served as Chief Financial...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD2.29M) is above average for companies of similar size in the US market ($USD1.07M).

Compensation vs Earnings: Insufficient data to compare Kevin's compensation with company performance.


Leadership Team

Experienced Management: LBPH's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: LBPH's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: LBPH only recently listed within the past 12 months.


Top Shareholders

Company Information

Longboard Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Longboard Pharmaceuticals, Inc.
  • Ticker: LBPH
  • Exchange: NasdaqGM
  • Founded: 2020
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$160.447m
  • Shares outstanding: 17.22m
  • Website: https://www.longboardpharma.com

Number of Employees


Location

  • Longboard Pharmaceuticals, Inc.
  • 6154 Nancy Ridge Drive
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 23:52
End of Day Share Price2021/10/19 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.